Latest Medical News from Russia

Treating patients who have already undergone standard lines of cancer therapy is a critical task for oncologists. The method of choice in such cases becomes therapy with radioisotopes, or radionuclide therapy (RNT). About these capabilities in Russia, in this Marus Media review.

In 2025, medicine has taken steps that are directly changing clinical practice: fundamental discoveries have begun to be converted into real solutions. In this digest we've assembled precisely such works.

Theranostics ("therapy" with "diagnosis") is one of the most promising and modern methods of cancer treatment. It is based on the use of radiopharmaceuticals that diagnose and simultaneously destroy cancer cells. Nidal Salim, Director of the EMC Institute of Oncology, told Marus Media when theranostics is used and exactly how it helps fight the tumor.

For the 9 months of 2025 compared to the same period in 2024, Russia's Ministry of Health recorded 25% growth in the financial volume of medical care provided to foreign citizens. The volume of treatment for patients with serious oncological, cardiological, and ophthalmological conditions increased particularly notably.

Thanks to government and private investment, Russia has created comprehensive nuclear medicine infrastructure over the past 20 years, a network of PET/CT diagnostic centers, SPECT/CT facilities at major multidisciplinary clinics, and "hot beds" for radiopharmaceutical treatment. This infrastructure is followed by radiopharmaceutical development and clinical trials, and theranostics development available in only a few countries. Read the full analysis on Marus Media.

Over the past 25 years of clinical use, preimplantation genetic testing (PGT) has made a significant technological breakthrough and has become an integral part of the IVF program. Dr. Zhanna Glinkina, a biologist, explains how new technologies have made the prevention of hereditary diseases more accessible and what future challenges lie ahead.

Russian health authorities have granted market authorization to Alectinib-Amedart, a domestically manufactured therapeutic designed to provide a more cost-effective and accessible alternative to the originator product Alecensa (alectinib, Roche). Alectinib represents a critical treatment option for patients with non-small cell lung cancer harboring specific genetic alterations.

A team of physicians from Mariinsky Hospital in St. Petersburg performed surgery involving simultaneous implantation of left and right artificial heart ventricles. BiVAD (Biventricular Assist Device) technology is one of the most complex in global cardiac surgery and is performed in only a handful of medical centers.

Geropharm plans to release a Russian analog of high-dose semaglutide – Wegovy from Novo Nordisk – an innovative weight loss medication. Currently, semaglutide therapy in Russia is only available in standard dosages.